The central government has launched ‘Mission Covid Suraksha’ to facilitate the development of around 5-6 Covid-19 vaccines. According to the Department of Biotechnology (DBT) of the Government of India, this will also ensure that, various vaccines are offered for market introduction and licensing.
DBT further noted that, this mission focuses on the preclinical phase as well as clinical development, through the manufacturing and regulatory facility to the end of the Kovid-19 vaccine development.
Earlier in November 2020, the Government of India announced a third incentive package of Rs 900 crore for the ‘Mission Covid Suraksha – Indian Covid-19 Vaccine Development Mission’.
Main characteristics
This mission will help accelerate the development of the Covid-19 vaccine.
Earlier, DBT had announced various programs for the development of Covid vaccine as well as other solutions related to Kovid but, this mission would be purely dedicated to vaccine development.
So far, a total of 10 vaccines have been supported by the Department of Biotechnology in the field of industry and education.
So far, 5 vaccine antagonists are undergoing human trials, including the Russian vaccine Sputnik-V, along with at least 3 other vaccines in advanced pre-clinical stages.
